USA - NYSE:INSP - US4577301090 - Common Stock
The current stock price of INSP is 81.79 USD. In the past month the price increased by 8.81%. In the past year, price decreased by -58.4%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.32 | 219.92B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.04 | 200.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.91 | 148.20B | ||
| SYK | STRYKER CORP | 27.03 | 136.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.18 | 56.68B | ||
| BDX | BECTON DICKINSON AND CO | 12.33 | 50.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.45 | 48.96B | ||
| RMD | RESMED INC | 25.4 | 36.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.92 | 33.35B | ||
| PODD | INSULET CORP | 69.98 | 22.51B | ||
| DXCM | DEXCOM INC | 29.57 | 21.57B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Inspire Medical Systems, Inc. is a medical technology company, which focuses on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The company is headquartered in Golden Valley, Minnesota and currently employs 1,246 full-time employees. The company went IPO on 2018-05-03. The firm is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The company has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The firm sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
INSPIRE MEDICAL SYSTEMS INC
5500 Wayzata Blvd Ste 1600
Golden Valley MINNESOTA 55416 US
CEO: TimothyP. Herbert
Employees: 1246
Phone: 17639575037
Inspire Medical Systems, Inc. is a medical technology company, which focuses on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The company is headquartered in Golden Valley, Minnesota and currently employs 1,246 full-time employees. The company went IPO on 2018-05-03. The firm is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The company has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The firm sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
The current stock price of INSP is 81.79 USD. The price decreased by -2.41% in the last trading session.
INSP does not pay a dividend.
INSP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
The next ex-dividend date for INSPIRE MEDICAL SYSTEMS INC (INSP) is November 7, 2022.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INSP.
INSPIRE MEDICAL SYSTEMS INC (INSP) currently has 1246 employees.
ChartMill assigns a technical rating of 2 / 10 to INSP. When comparing the yearly performance of all stocks, INSP is a bad performer in the overall market: 89.78% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to INSP. INSP has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months INSP reported a non-GAAP Earnings per Share(EPS) of 2.04. The EPS increased by 90.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.17% | ||
| ROA | 6.62% | ||
| ROE | 7.84% | ||
| Debt/Equity | 0 |
26 analysts have analysed INSP and the average price target is 127.13 USD. This implies a price increase of 55.43% is expected in the next year compared to the current price of 81.79.
For the next year, analysts expect an EPS growth of -70.2% and a revenue growth 13.03% for INSP